Evaluating Perioperative Chemotherapy for Pancreatic Cancer
Perioperative chemotherapy treatment did not improve overall survival for patients with resectable pancreatic cancer, according to a recent Northwestern Medicine clinical trial.
Monthly Archives: February, 2021
Celebrating 75 Years of Partnership with the VA
A model forged at Northwestern, academic affiliations with Veteran’s hospitals changed American medicine — providing care for veterans, training for future physicians and advancing scientific discovery.
Blocking Cell Division in Glioblastoma
Blocking the arginine methylation pathway, which helps brain tumor cells proliferate by promoting cell division, could improve cancer therapies, according to a recent study.
Northwestern Investigators Explore COVID-19 Treatments
Working with large, multicenter teams, Northwestern clinician-scientists have examined treatments for blood clotting in critically ill patients with COVID-19, and explored therapies that could reduce disease progression and hospitalization.
Tackling Inflammation to Improve Heart Attack Recovery
Inhibiting an inflammatory pathway reduced heart attack-induced damage in experimental models, according to a recent Northwestern Medicine study.
Physical Therapy Student Helps Save a Life
Alyssa Martinez, a second-year student in the Doctor of Physical Therapy (DPT) program, recently put her newly acquired medical skills to use to help save a man’s life.
Untangling Cellular Changes in Pediatric Epilepsy
For the first time, Northwestern Medicine scientists have characterized how a genetic mutation associated with pediatric epilepsy affects neuron activity.
Inhibiting Protein Degradation May Prevent Cocaine-Induced Reward Behaviors
Northwestern Medicine investigators have discovered that inhibiting a specific autophagy protein found in dopaminergic neurons may prevent reward-related behaviors induced by cocaine misuse.
Identifying Therapeutic Targets for B-cell Acute Lymphoblastic Leukemia
Northwestern Medicine investigators have identified a protein kinase called DYRK1A and its downstream substrates as potential therapeutic targets for treating pediatric patients with B-cell acute lymphoblastic leukemia.
Antibody Drug Improves Survival for Aggressive Breast Cancer
A new antibody drug demonstrated similar efficacy to currently available therapies to treat advanced ERBB2-positive breast cancer, according to a recent clinical trial.